First human trial of SUPLEXA cells targets Hard-to-Treat cancers
NCT ID NCT05237206
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a new therapy called SUPLEXA in 46 adults with advanced solid tumors or blood cancers that had spread. SUPLEXA is made from a patient's own immune cells, which are processed in a lab to become more active against cancer. The main goal was to check safety and find the right dose, with a secondary goal of seeing if tumors shrink. Because it is a Phase 1 study, it is too soon to know if this will become a standard treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SUPLEXA therapeutic cells (a mix of immune cells made from the patient's own blood)
What this could lead to
If it works, this could point toward a new way to treat advanced cancers that have not responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The treatment may not shrink tumors or may cause side effects. Only solid tumor patients were enrolled, so results may not apply to blood cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Research Sa (Crsa)
Adelaide, South Australia, 5000, Australia
-
Greenslopes Private Hospital/Gallipoli Medical Research Foundation
Brisbane, Queeensland, 4120, Australia
-
Southern Oncology Clinical Research Unit (SOCRU)
Adelaide, South Australia, 5042, Australia